CytomX Therapeutics to Present at Upcoming February Conferences
Rhea-AI Summary
CytomX Therapeutics (Nasdaq: CTMX) announced management will present at two investor conferences in February 2026: Guggenheim Emerging Outlook: Biotech Summit on Feb 11, 2026 (fireside chat at 4:30 p.m. ET) and World ADC London on Feb 25, 2026 (presentation at 5:00 p.m. GMT).
Investors can find schedules and webcast details on the company's Events and Presentations page.
Positive
- None.
Negative
- None.
Market Reaction
Following this news, CTMX has gained 4.37%, reflecting a moderate positive market reaction. Our momentum scanner has triggered 2 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $6.34. This price movement has added approximately $45M to the company's valuation.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.
Key Figures
Market Reality Check
Peers on Argus
CTMX slipped -0.33% ahead of this non-fundamental news. Most close biotech peers (ADCT, AUTL, IMAB, LRMR) also showed modest declines, while TECX was slightly positive, and no peers appeared in the momentum scanner, pointing to stock-specific rather than coordinated sector momentum.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 08 | Business update | Positive | -0.9% | Outlined 2026 milestones for CX-2051 and CX-801 pipeline programs. |
| Nov 25 | Investor conferences | Neutral | +4.5% | Announced December 2025 presentations at major healthcare investor conferences. |
| Nov 13 | Investor conference | Neutral | -8.8% | Jefferies London fireside chat and investor meetings disclosure. |
| Nov 06 | Earnings update | Neutral | -0.5% | Reported Q3 2025 financials and reiterated CX-2051 and CX-801 progress. |
| Nov 04 | Clinical data | Positive | +4.1% | Presented CX-801 Phase 1 biomarker data supporting ongoing combination study. |
Conference and data-related announcements have often aligned with market reactions, while a recent broader business update saw a contrary, negative move.
Over the last few months, CytomX has mixed operational updates with frequent conference participation. A Nov 4, 2025 SITC biomarker update for CX-801 coincided with a positive move, while the Nov 6, 2025 Q3 earnings/business update saw only a slight decline. Subsequent December and November 2025 conference appearances produced both gains and losses. The Jan 8, 2026 2026 business and clinical milestone update was followed by a small drop, showing occasional divergence between seemingly constructive news and near-term price action.
Regulatory & Risk Context
The company has an active S-3 shelf registration dated 2025-08-07 that is currently recorded as not yet effective, with 0 recorded prospectus usages in the context provided.
Market Pulse Summary
This announcement centers on CytomX management presenting at the Guggenheim biotech summit on February 11, 2026 and World ADC London on February 25, 2026, a continuation of its active conference presence. Recent history shows conference and data updates often align with market moves, while broader business updates sometimes diverge. With shares trading above the 200-day MA and an active but unused S-3 shelf, investors may focus on any new clinical or partnering details shared at these events.
Key Terms
biologics medical
AI-generated analysis. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following conferences in February.
Guggenheim Emerging Outlook: Biotech Summit 2026
Date: Wednesday, February 11, 2026
Fireside Chat: 4:30 p.m. ET
Location: New York, NY
World ADC London 2026
Date: Wednesday, February 25, 2026
Presentation: 5:00 p.m. GMT
Location: London, UK
Additional information can be found on the Events and Presentations page of CytomX’s website at www.cytomx.com.
About CytomX Therapeutics, Inc.
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked biologics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY® therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), T-cell engagers, and immune modulators such as cytokines. CytomX’s clinical-stage pipeline includes varsetatug masetecan (formerly CX-2051) and CX-801. Varseta-M is a masked, conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM), armed with a topoisomerase-1 inhibitor payload and was discovered in collaboration with ImmunoGen, now part of AbbVie. EpCAM is a highly expressed but previously undruggable tumor antigen due to expression on normal tissues. Varseta-M is designed to open a therapeutic window for this high potential target and deliver meaningful anti-cancer activity in solid tumors, including CRC. CX-801 is a masked interferon alpha-2b PROBODY® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and X (formerly Twitter).
Company Contact:
Chris Ogden
SVP, Chief Financial Officer
cogden@cytomx.com
Investor Contact:
Precision AQ (formerly Stern Investor Relations)
Stephanie Ascher
stephanie.ascher@precisionaq.com
Media Contact:
Precision AQ
Colleen Ketchum
colleen.ketchum@precisionaq.com
FAQ
When will CytomX (CTMX) present at the Guggenheim Emerging Outlook: Biotech Summit in February 2026?
What time is CytomX's (CTMX) World ADC London 2026 presentation on February 25, 2026?
Where can investors find the CytomX (CTMX) conference schedule and webcast details for February 2026?
Will CytomX (CTMX) provide investor updates during the February 2026 conferences?
How can I attend or view CytomX (CTMX) presentations at the February 2026 conferences?
